Brief: Impressive Results From Cytodyn’S Phase 2 Covid-19 Trial

Cytodyn

21/07/2020 11:59

July 21 (Reuters) - Cytodyn Inc  CYDY.PK :
    * IMPRESSIVE RESULTS FROM CYTODYN’S PHASE 2 COVID-19 TRIAL
    * CYTODYN - 39% OF PATIENTS IN PLACEBO ARM HAD SAES AS
COMPARED TO
ONLY 14% OF PATIENTS IN LERONLIMAB ARM HAD SAES, WHICH WERE
UNRELATED TO LERONLIMAB
    * CYTODYN INC - SAFETY DATA OF LERONLIMAB SHOWS 5 PATIENTS
OUT OF
56 (ABOUT 9%) REPORTED SERIOUS ADVERSE EVENTS, NONE WERE RELATED
TO LERONLIMAB
    * CYTODYN INC - OF 84 PATIENTS TREATED, ONE PATIENT DIED 33
DAYS
AFTER ENROLLMENT DUE TO AN EVENT UNRELATED TO LERONLIMAB

Source text for Eikon:  ID:nGNXc9Q4Fq 
Further company coverage:  CYDY.PK 

 ((Reuters.Briefs@thomsonreuters.com;))